BioNTech Phase 3 trial of variant-adapted BNT162b2 COVID vaccine recruitingSep 30Weekly roundup, 7 itemsatirmociclibberobenatide
Lilly posts Lyumjev safety results in India; registers new Alzheimer's Phase 1 studySep 29Weekly roundup, 5 itemsbaricitinibCipla
Lilly's orforglipron posts Phase 3 diabetes results; six new trials registeredSep 18Weekly roundup, 7 itemsEli Lillyorforglipron
Lilly posts Phase 3 orforglipron results; two more programs report terminated-trial dataSep 4Weekly roundup, 7 itemsEli Lillylasmiditan
Pfizer posts MET097 obesity results; registers new Phase 3 obesity and dermatitis trialsAug 28Weekly roundup, 6 itemsberobenatidePF-08154225
FDA approves two efficacy supplements for Eli Lilly's MounjaroAug 27Regulatory decisionEli Lillytirzepatide
FDA approves efficacy supplement for Lilly's Zepbound (tirzepatide)Aug 26Regulatory decisionEli Lillytirzepatide
Lilly posts orforglipron Phase 3 results; adds new early-phase studiesAug 14Weekly roundup, 6 itemsbaricitinibbrenipatide
Lilly raises 2026 revenue guidance to $85-87 billion on Mounjaro, Zepbound growthAug 5Quarterly updateEli Lillytirzepatide
Lilly-linked tirzepatide alopecia trial joins mazisotine results, eloralintide recruitingJul 31Weekly roundup, 3 itemsEli Lillyeloralintide
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib
Sign inSign in